Skip to main content

Table 4 The effect of Matrix Model treatment, MPH and matrix-methylphenidate on clinical parameters in METH users 1

From: The therapeutic effects of methylphenidate and matrix-methylphenidate on addiction severity, craving, relapse and mental health in the methamphetamine use disorder

Group

Variable

Matrix (n = 20)

Methylphenidate (n = 22)

Matrix combination with methylphenidate (n = 21)

Control (n = 22)

P-value*

Effect size

DDQ2 Baseline

53.4 ± 6.4

53.9 ± 4.8

54.9 ± 4.5

55.9 ± 4.5

< 0.001

0.387

 End-of-trial

53.7 ± 5.7a

51.2 ± 4.0

49.4 ± 5.5

56.4 ± 3.7b

P-value**

0.701

< 0.001

< 0.001

0.291

  

LDQ3 Baseline

21.2 ± 2.8

20.6 ± 2.6

22.3 ± 2.9

20.8 ± 2.8

< 0.001

0.226

 End-of-trial

21.9 ± 2.9a

19.5 ± 2.3

19.3 ± 1.4

20.2 ± 1.6

P-value**

0.410

0.004

< 0.001

0.304

  

GHQ4 Baseline

31.4 ± 4.9

28.2 ± 6.6

30.9 ± 4.8

31.4 ± 5.3

0.001

0.178

 End-of-trial

30.3 ± 4.2

27.6 ± 5.2

27.0 ± 5.0c

30.6 ± 5.5

P-value**

0.096

0.480

< 0.001

0.195

  
  1. 1 Data are mean ± SDs
  2. 2 DDQ: Desire for Drug Questionnaire
  3. 3 LDQ: Leeds Dependence Questionnaire
  4. 4 GHQ: General Health Questionnaire
  5. a: Significant difference between Matrix with Methylphenidate and Matrix combination with methylphenidate groups (Bonferroni test)
  6. b: Significant difference between Control with Methylphenidate and Matrix combination with methylphenidate groups (Bonferroni test)
  7. c: Significant difference between Matrix combination with methylphenidate with other groups (Bonferroni test)
  8. * ANCOVA test/ ** Paired t-test